On August 24, 2021, ICER released a revised version of a final evidence report from 2018 evaluating the clinical and cost effectiveness of three emerging treatments for hereditary angioedema. Unfortunately, while ICER tried to update its analysis -- supposedly to...

On August 18, 2021, ICER released its draft evidence report, “Tezepelumab for Severe Asthma: Effectiveness and Value.” This is the first step in ICER’s standard process that – after a period of public comment – will result in the release of final evidence report,...

On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This is the first step in ICER’s process that, if the announced schedule holds, will lead to the release of final evidence report in...

On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the...

On August 5, 2021, ICER issued its Final Evidence Report on aducanumab, a first-of-its-kind medication created to treat Alzheimer’s disease. Following its typical process for gathering information – which included the solicitation of public comments and a public...

On Monday, July 19th, the Pioneer Institute and the Pacific Research Institute (PRI) will host a virtual webinar, titled: Policy Measures on Drug Value: Does ICER’s Approach Improve Patient Access & Equity? The event will feature prominent experts in a discussion...

Patients Rising – in coordination with Gravis Marketing, a leading market research and polling firm – recently conducted a survey to better understand American voters’ views on national health issues. The data from the survey – which was conducted in late April and...